Navigation Links
AcuNetx Announces Change in Trading Status
Date:9/3/2010

TORRANCE, Calif., Sept. 3 /PRNewswire/ -- AcuNetx, Inc. (OTC Bulletin Board: ANTXE) today announced that it had received a communication from the Financial Industry Regulatory Authority (FINRA) to the effect that its Common Stock would be removed from quotation on the OTC Bulletin Board on September 3, 2010.

The letter indicated that FINRA took the action because AcuNetx has been delinquent in its filings under the Exchange Act three times in the past two years, and NASD Rule 6530 provides for removal from quotation in this instance. AcuNetx has the right to appeal the decision, and is considering whether to file such an appeal.

Robert S. Corrigan, President of AcuNetx, said, "We plan to continue filing reports and financial statements with the SEC, and we expect that our stock will continue to be quoted and traded in the over-the counter market (Pink Sheets)." He added, "Accordingly, we believe this action will not have any effect on our shareholders, and should have no effect on the liquidity of our Common Stock."

Corrigan explained that AcuNetx had timely filed its 10-Q for the quarter ended June 30, 2010. However, since AcuNetx had earlier dismissed its independent certified public accountants and has not engaged new accountants, the financial statements in the 10-Q were not reviewed by outside accountants, as contemplated by SEC accounting rules. FINRA took the position that, because of this, the filing was deficient.

"We are actively interviewing accounting firms, and plan to retain a new firm in the coming weeks," said Corrigan. "Once retained, we will ask the new accountants to review our current 10-Q filings and amend them if necessary."

About AcuNetx, Inc.:

AcuNetx markets a diverse line of diagnostic, analytical and therapeutic tools for medical (audiologists, neurologists, otolaryngologists and physical therapists as well as hospitals, clinics, and extended care facilities) and law enforcement applications. R&D applications include patent-pending technology for the physiological detection of deception (polygraph). AcuNetx is headquartered in Torrance, CA. For more information concerning AcuNetx and its subsidiaries, please visit www.acunetx.com.

Safe Harbor for Forward Looking Statements:

This news release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements represent management's opinion. While management believes such representations to be accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risks and uncertainties. Important factors that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission. FOR FURTHER INFORMATION CONTACT:Name:  Robert CorriganE-Mail:  rscorrigan@acunetx.com
'/>"/>

SOURCE AcuNetx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... , July 12, 2017 CarpalAID is a revolutionary new ... or surgery. Carpal tunnel syndrome affects more than 8 ... twice the rate of men. The common methods of treating CTS ... with uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn ...
(Date:7/11/2017)... July 11, 2017  Sysmex America, Inc., a ... testing equipment as well as middleware information systems ... to make quality assurance easier and more risk ... well known for the innovation that it delivers ... elevates quality assurance processes to a new level ...
(Date:7/10/2017)...  BDI Group subsidiary Pathway Purchasing Network, a ... serving specialty pharmacies, home infusion companies and physician ... value-added member programs designed to help organizations gain ... improve access and affordability for patients who rely ... Pathway has worked with ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... Dr. Jig Patel is pleased to announce openings ... without a referral. Understanding the difficulties that face people who are missing teeth ... permanent alternative to removable dentures and bridges. Not only does an implant improve oral ...
(Date:7/20/2017)... ... 19, 2017 , ... Western University of Health Sciences College ... grant to train predoctoral dental students in providing care to vulnerable children ages ... , The Predoctoral Pediatric Training Project (PPTP), a five-year grant, recognizes the curriculum ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/18/2017)... ... 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in the creation ... WORLDZ Summit, taking place in Hollywood from July 31-August 1, the Company’s Founder ... for both pediatric and adult patients, and how the path has led her to ...
(Date:7/18/2017)... , ... July 18, 2017 , ... The results of an international clinical trial, led ... therapy for a severe type of muscular dystrophy holds promise for a subgroup of patients. ... Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical ...
Breaking Medicine News(10 mins):